Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Decreases By 52.7%

Akari Therapeutics, Plc (NASDAQ:AKTX) was the recipient of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 18,500 shares, a decrease of 52.7% from the September 30th total of 39,100 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average trading volume of 16,100 shares, the days-to-cover ratio is presently 1.1 days.

Akari Therapeutics Price Performance

Shares of NASDAQ:AKTX opened at $2.32 on Friday. Akari Therapeutics has a 1 year low of $1.08 and a 1 year high of $4.40. The company’s 50 day simple moving average is $3.12 and its 200 day simple moving average is $2.73.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Akari Therapeutics in a research report on Friday. They issued a “sell” rating on the stock.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.